Read by QxMD icon Read


Hong Ma, Shuo Yu, Xiaojing Liu, Yingao Zhang, Thomas Fakadej, Ziqing Liu, Chaoying Yin, Weining Shen, Jason W Locasale, Joan M Taylor, Li Qian, Jiandong Liu
BACKGROUND: Hypertrophic response to pathological stimuli is a complex biological process that involves transcriptional and epigenetic regulation of the cardiac transcriptome. Though previous studies have implicated transcriptional factors and signaling molecules in pathological hypertrophy, the role of RNA-binding protein (RBP) in this process has received little attention. METHODS: Here we used transverse aortic constriction (TAC) and in vitro cardiac hypertrophy models to characterize the role of an evolutionary conserved RBP Lin28a in pathological cardiac hypertrophy...
January 14, 2019: Circulation
Clare Oliver-Williams, Michael Sweeting, Jo Jacomelli, Lisa Summers, Anne Stevenson, Tim Lees, Jonothan J Earnshaw
BACKGROUND: Population screening for abdominal aortic aneurysm (AAA) has commenced in several countries, and has been shown to reduce AAA-related mortality by up to 50%. Most men who screen positive have an AAA below 5.5cm in diameter, the referral threshold for treatment, and are entered into an ultrasound surveillance programme. This study aimed to determine the risk of ruptured AAA (rAAA) in men under surveillance. METHODS: Men in the NHS AAA Screening Programme who initially had a small (3-4...
January 14, 2019: Circulation
Francesco Franchi, Fabiana Rollini, Andrea Rivas, Mustafa Wali, Maryuri Briceno, Malhar Agarwal, Zubair Shaikh, Ahmed Nawaz, Gabriel Silva, Latonya Been, Ramez Smairat, Marc Kaufman, Andres Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Theodore A Bass, Dominick J Angiolillo
BACKGROUND: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (P-PCI). In turn, this leads to a gap in platelet inhibition exposing patients to an increased risk of early thrombotic complications underscoring the need to define strategies associated with more effective platelet inhibition in the peri-PCI period. Cangrelor is an intravenous P2Y12 inhibitor with prompt and potent antiplatelet effects...
January 11, 2019: Circulation
Poghni Allen Peri-Okonny, Kedryn K Baskin, Gary Iwamoto, Jere H Mitchell, Scott A Smith, Han Kyul Kim, Luke I Szweda, Rhonda Bassel-Duby, Teppei Fujikawa, Carlos M Castorena, James Richardson, John M Shelton, Colby Ayers, Jarett D Berry, Venkat S Malladi, Ming-Chang Hu, Orson W Moe, Philipp E Scherer, Wanpen Vongpatanasin
No abstract text is available yet for this article.
January 7, 2019: Circulation
Tali Elfassy, Samuel L Swift, M Maria Glymour, Sebastian Calonico, David R Jacobs, Elizabeth R Mayeda, Kiarri N Kershaw, Catarina Kiefe, Adina Zeki Al Hazzouri
No abstract text is available yet for this article.
January 7, 2019: Circulation
Diane Treat-Jacobson, Mary M McDermott, Ulf G Bronas, Umberto Campia, Tracie C Collins, Michael H Criqui, Andrew W Gardner, William R Hiatt, Judith G Regensteiner, Kathleen Rich
No abstract text is available yet for this article.
December 13, 2018: Circulation
(no author information available yet)
Retraction Please see the following related article: Circulation. 2014;129:157-172.
December 12, 2018: Circulation
(no author information available yet)
Retraction Please see the following related article: Circulation. 2013;128:2211-2223.
December 12, 2018: Circulation
(no author information available yet)
Retraction Please see the following related article: Circulation. 2011;123:1287-1296.
December 12, 2018: Circulation
Ke Yuan, Elya A Shamskhou, Mark E Orcholski, Abinaya Nathan, Sushma Reddy, Hiroaki Honda, Vigneshwaran Mani, Yitian Zeng, Mehmet O Ozen, Lingli Wang, Utkan Demirci, Wen Tian, Mark R Nicolls, Vinicio A de Jesus Perez
BACKGROUND: Pulmonary arterial hypertension (PAH) is a life-threatening disorder of the pulmonary circulation associated with loss and impaired regeneration of microvessels. Reduced pericyte coverage of pulmonary microvessels is a pathological feature of PAH and is partly due to the inability of pericytes to respond to signaling cues from neighboring pulmonary microvascular endothelial cells (PMVECs). We have shown that activation of the Wnt/PCP pathway is required for pericyte recruitment but whether production and release of specific Wnt ligands by PMVECs is responsible for Wnt/PCP activation in pericytes is unknown...
December 11, 2018: Circulation
Zhiyuan Ma, Yen-Rei Yu, Cristian T Badea, Jeffrey J Kovacs, Xinyu Xiong, Suzy Comhair, Claude A Piantadosi, Sudarshan Rajagopal
BACKGROUND: Receptor signaling is central to vascular endothelial function and is dysregulated in vascular diseases such as atherosclerosis and pulmonary arterial hypertension (PAH). Signaling pathways involved in endothelial function include vascular endothelial growth factor receptors (VEGFRs) and G protein-coupled receptors (GPCRs), which classically activate distinct intracellular signaling pathways and responses. The mechanisms that regulate these signaling pathways have not been fully elucidated and it is unclear what nodes for crosstalk exist between these diverse signaling pathways...
December 11, 2018: Circulation
Kristen J Bubb, Aisah A Aubdool, Amie J Moyes, Sarah Lewis, Jonathan P Drayton, Owen Tang, Vedanta Mehta, Ian C Zachary, David J Abraham, Janice Tsui, Adrian J Hobbs
BACKGROUND: Angiogenesis and vascular remodeling are complementary, innate responses to ischemic cardiovascular events, including peripheral artery disease (PAD) and myocardial infarction, which restore tissue blood supply and oxygenation; the endothelium plays a critical function in these intrinsic protective processes. C-type natriuretic peptide (CNP) is a fundamental endothelial signaling species that coordinates vascular homeostasis. Herein, we sought to delineate a central role for CNP in angiogenesis and vascular remodeling in response to ischemia...
December 11, 2018: Circulation
Dayna A Johnson, S Justin Thomas, Marwah Abdalla, Na Guo, Yuichiro Yano, Michael Rueschman, Rikki M Tanner, Murray A Mittleman, David A Calhoun, James G Wilson, Paul Muntner, Susan Redline
BACKGROUND: Blacks have a high prevalence of hypertension and uncontrolled blood pressure (BP), each of which may be partially explained by untreated sleep apnea. We investigated the association of sleep apnea with uncontrolled BP and resistant hypertension in blacks. METHODS: Between 2012 and 2016, Jackson Heart Sleep Study participants (N=913) underwent an in-home Type 3 sleep apnea study, clinic BP measurements, and anthropometry. Moderate or severe obstructive sleep apnea (OSA) was defined as a respiratory event index ≥15, and nocturnal hypoxemia was quantified as percent sleep time with <90% oxyhemoglobin saturation...
December 10, 2018: Circulation
Daniel Modin, Mads Emil Jørgensen, Gunnar Gislason, Jan Skov Jensen, Lars Køber, Brian Claggett, Sheila M Hegde, Scott D Solomon, Christian Torp-Pedersen, Tor Biering-Sørensen
BACKGROUND: Influenza infection is a serious event for patients with heart failure (HF). Little knowledge exists about the association between influenza vaccination and outcome in patients with HF. This study sought to determine whether influenza vaccination is associated with improved long-term survival in patients with newly diagnosed HF. METHODS: We performed a nationwide cohort study including all patients who were >18 years of age and diagnosed with HF in Denmark in the period of January 1, 2003, to June 1, 2015 (n=134048)...
December 10, 2018: Circulation
Michael J Pencina, Ann Marie Navar, Daniel Wojdyla, Robert J Sanchez, Irfan Khan, Joseph Elassal, Ralph B D'Agostino, Eric D Peterson, Allan D Sniderman
BACKGROUND: To optimize preventive strategies for coronary heart disease (CHD), it is essential to understand and appropriately quantify the contribution of its key risk factors. Our objective was to compare the associations of key modifiable CHD risk factors-specifically lipids, systolic blood pressure (SBP), diabetes, and smoking-with incident CHD events based on their prognostic performance, attributable risk fractions, and treatment benefits, overall and by age. METHODS: Pooled participant-level data from four observational cohort studies sponsored by the National Heart, Lung, and Blood Institute were used to create a cohort of 22,626 individuals aged 45-84 years who were initially free of cardiovascular disease...
December 7, 2018: Circulation
Ivana Zlatanova, Cristina Pinto, Philippe Bonnin, Jacques R R Mathieu, Wineke Bakker, José Vilar, Mathilde Lemitre, David Voehringer, Sophie Vaulont, Carole Peyssonnaux, Jean-Sébastien Silvestre
BACKGROUND: Defective systemic and local iron metabolism correlates with cardiac disorders. Hepcidin, a master iron sensor, actively tunes iron trafficking. We hypothesized that hepcidin could play a key role to locally regulate cardiac homeostasis following acute myocardial infarction (AMI). METHODS: Cardiac repair was analyzed in mice harboring specific cardiomyocyte or myeloid cell deficiency of hepcidin and challenged with AMI. RESULTS: We found that the expression of hepcidin was elevated after AMI and the specific deletion of hepcidin in cardiomyocytes failed to improve cardiac repair and function...
December 7, 2018: Circulation
David Fitchett, Silvio E Inzucchi, Christopher P Cannon, Darren K McGuire, Benjamin M Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T George, Bernard Zinman
BACKGROUND: In the EMPA-REG OUTCOME trial in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), compared with placebo, empagliflozin reduced the risks of 3-point major adverse CV events (3-point MACE), CV and all-cause death and hospitalization for heart failure (HHF). We investigated whether these effects varied across the spectrum of baseline CV risk. METHODS: CV death, all-cause mortality, 3-point MACE and HHF in the pooled empagliflozin and placebo groups were analyzed in subgroups by prior myocardial infarction (MI) and/or stroke at baseline, and by estimated baseline CV risk based on the 10-point TIMI Risk Score for Secondary Prevention (TRS 2°P)...
December 6, 2018: Circulation
Duk-Hyun Kang, Sung-Ji Park, Sung-Hee Shin, Geu-Ru Hong, Sahmin Lee, Min-Seok Kim, Sung-Cheol Yun, Jong-Min Song, Seung-Woo Park, Jae-Joong Kim
BACKGROUND: The morbidity and mortality of patients with functional mitral regurgitation (MR) remain high, but no pharmacological therapy has been proven effective. The hypothesis of this study was that sacubitril/valsartan would be superior to valsartan alone in improving functional MR via dual inhibition of the renin-angiotensin system and neprilysin. METHODS: In this double-blind trial, we randomly assigned 118 heart failure patients with chronic functional MR secondary to left ventricular (LV) dysfunction to receive either sacubitril/valsartan or valsartan, in addition to standard medical therapy for heart failure...
December 5, 2018: Circulation
Benedikt Schrage, Karim Ibrahim, Tobias Loehn, Nikos Werner, Jan-Malte Sinning, Federico Pappalardo, Marina Pieri, Carsten Skurk, Alexander Lauten, Ulf Landmesser, Ralf Westenfeld, Patrick Horn, Matthias Pauschinger, Dennis Eckner, Raphael Twerenbold, Peter Nordbeck, Tim Salinger, Peter Abel, Klaus Empen, Mathias C Busch, Stephan B Felix, Jan Thorben Sieweke, Jacob Eifer Møller, Nilesh Pareek, Jonathan Hill, Philip MacCarthy, Martin W Bergmann, José P S Henriques, Sven Möbius-Winkler, P Christian Schulze, Taoufik Ouarrak, Uwe Zeymer, Steffen Schneider, Stefan Blankenberg, Holger Thiele, Andreas Schäfer, Dirk Westermann
BACKGROUND: Percutaneous mechanical circulatory support devices are increasingly used in acute myocardial infarction complicated by cardiogenic shock (AMI-CS), despite limited evidence for their effectiveness. The aim of this study was to evaluate outcomes associated with use of the Impella device compared with IABP and medical treatment in patients with AMI-CS. METHODS: Data of patients with AMI-CS treated with the Impella device at European tertiary care hospitals was collected retrospectively...
December 5, 2018: Circulation
Nienke van Rein, Uffe Heide-Jørgensen, Willem M Lijfering, Olaf M Dekkers, Henrik Toft Sørensen, Suzanne C Cannegieter
BACKGROUND: Patients with atrial fibrillation generally require anticoagulant therapy, and at times therapy with additional platelet aggregation inhibitors. Data are scarce on bleeding rates in high-risk groups receiving combination therapy, such as the elderly or patients with a high CHA2 DS2 -VASc score. METHODS: We conducted a nationwide cohort study of Danish atrial fibrillation patients aged 50 years or older. Treatments were ascertained from a prescription database...
December 5, 2018: Circulation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"